Purple pitcher plant

Identification

Generic Name
Sarracenia Purpurea
Commonly known or available as Purple pitcher plant
DrugBank Accession Number
DB13965
Background

Sarracenia purpurea, commonly known as the purple pitcher plant, northern pitcher plant, turtle socks, or side-saddle flower, is a perennial carnivorous plant in the family Sarraceniaceae. Sarracenia purpurea attract and trap insects within their pitchers, or fused leaves, to consume nitrogen during the digestion process 1. It is widely distributed across North America and has been used as a traditional medicinal herb in many aboriginal communities 1,2. It was used as an injectable pain reliever and during the 19th century, Sarracenia purpurea was used as a treatment of smallpox 1. Compounds extracted from Sarracenia purpurea include phenolic glycosides, flavonoid glycosides, and iridoids. In vitro, there is evidence of glycosides potentiating glucose uptake with potential antidiabetic properties 2. Cytoprotection in an in vitro model of diabetic neuropathy has also been studied. However, the use of Sarracenia Purpurea extracts in the clinical setting are limited.

Type
Biotech
Groups
Approved, Experimental
Synonyms
  • Frog's-britches whole
  • Huntsman's-horns whole
  • Pitcher plant
  • Pitcherplant whole
  • Purple pitcherplant whole
  • Sarracenia purpura
  • Sarracenia purpurea l.
  • Sarracenia purpurea whole
  • Sarracenia rosea whole
  • Sidesaddle-flower whole

Pharmacology

Indication

No approved therapeutic indications.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Symptomatic treatment ofPain•••••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Extracts of Sarracenia purpurea may enhance glucose uptake by attenuating glucose-6-phosphatase enzymatic activity and decreasing hepatic glucose production 2. In an in vitro model of glucotoxicity in PC12 cells, treatment of Sarracenia purpurea demonstrated cytoprotective effects and prevented glucose-mediated cell loss 1.

Mechanism of action

The full mechanism of action of the antidiabetic and cytoprotective activity is not fully elucidated.

Absorption

No pharmacokinetic data available.

Volume of distribution

No pharmacokinetic data available.

Protein binding

No pharmacokinetic data available.

Metabolism

No pharmacokinetic data available.

Route of elimination

No pharmacokinetic data available.

Half-life

No pharmacokinetic data available.

Clearance

No pharmacokinetic data available.

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

No toxicokinetic data available.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
P-BlocInjection12.5 mg/1mLParenteralCreative Science, Llc2004-11-202019-07-01US flag
SarapinInjection0.17 g/1mLIntramuscularHigh Chemical Company1935-01-312016-06-10US flag
SarapinSolution100 %IntramuscularHigh Chemical Company1942-12-312019-04-30Canada flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
P-BlocSarracenia Purpurea (12.5 mg/1mL)InjectionParenteralCreative Science, Llc2004-11-202019-07-01US flag
SarapinSarracenia Purpurea (0.17 g/1mL)InjectionIntramuscularHigh Chemical Company1935-01-312016-06-10US flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
FOP08H143P
CAS number
Not Available

References

General References
  1. Harris CS, Asim M, Saleem A, Haddad PS, Arnason JT, Bennett SA: Characterizing the cytoprotective activity of Sarracenia purpurea L., a medicinal plant that inhibits glucotoxicity in PC12 cells. BMC Complement Altern Med. 2012 Dec 5;12:245. doi: 10.1186/1472-6882-12-245. [Article]
  2. Muhammad A, Guerrero-Analco JA, Martineau LC, Musallam L, Madiraju P, Nachar A, Saleem A, Haddad PS, Arnason JT: Antidiabetic compounds from Sarracenia purpurea used traditionally by the Eeyou Istchee Cree First Nation. J Nat Prod. 2012 Jul 27;75(7):1284-8. doi: 10.1021/np3001317. Epub 2012 Jun 27. [Article]
RxNav
1605249

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
InjectionParenteral12.5 mg/1mL
InjectionIntramuscular0.17 g/1mL
SolutionIntramuscular100 %
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Drug created at January 17, 2018 18:40 / Updated at March 28, 2024 03:23